Articles published by Cleerly

Cleerly's TRANSFORM Trial Sends a Mobile CT Scanner Across the South to Reach Patients in Underserved Communities

October 08, 2026

From Cleerly

Via Business Wire

Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk

September 02, 2026

From Cleerly

Via Business Wire

Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease

July 30, 2026

From Cleerly

Via Business Wire

Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026

July 07, 2026

From Cleerly

Via Business Wire

Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26

March 25, 2026

From Cleerly

Via Business Wire

Cleerly AI-QCT Demonstrates High Agreement with Invasive IVUS in INVICTUS Registry

March 20, 2026

From Cleerly

Via Business Wire

Aetna Approves Coverage for Cleerly's AI Cardiovascular Imaging Analysis

January 06, 2026

From Cleerly

Via Business Wire

CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease

December 15, 2025

From Cleerly

Via Business Wire

Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025

November 26, 2025

From Cleerly

Via Business Wire

AHA 2025 Late-Breaking Science: Cleerly’s AI Atherosclerosis Quantification Outperforms Traditional Risk Scoring

November 10, 2025

From Cleerly

Via Business Wire

TCT 2025 Late-Breaking Science: Quantitative Assessment of Non-Calcified Plaque Volume Drives Risk for Myocardial Infarction and Death

October 27, 2025

From Cleerly

Via Business Wire

UnitedHealthcare and Cigna Coverage for Cleerly LABS Advanced Plaque Analysis Begins October 1st

September 30, 2025

From Cleerly

Via Business Wire

Cigna Approves Coverage for Cleerly's AI Cardiovascular Imaging Technology

September 24, 2025

From Cleerly

Via Business Wire

Cleerly Demonstrates Significant Cardiovascular Risk Prediction in Late-Breaking Clinical Science at European Society of Cardiology Congress 2025

September 03, 2025

From Cleerly

Via Business Wire

Cleerly to Showcase New AI-QCT Research at SCCT2025 Annual Meeting

July 09, 2025

From Cleerly

Via Business Wire

Cleerly Announces Key Leadership Promotions: Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer

July 01, 2025

From Cleerly

Via Business Wire

AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection

May 06, 2025

From Cleerly

Via Business Wire

Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25

March 31, 2025

From Cleerly

Via Business Wire

Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25

March 27, 2025

From Cleerly

Via Business Wire

Cleerly Brings Advanced AI Heart Imaging to the American College of Cardiology’s Chicago Community Health Fair

March 25, 2025

From Cleerly

Via Business Wire

Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care

March 04, 2025

From Cleerly

Via Business Wire

Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024

November 13, 2024

From Cleerly

Via Business Wire

Cleerly Presents Late-Breaking Research on AI-Enabled Quantitative CT Coronary Assessment for Predicting Major Adverse Cardiovascular Events at TCT 2024

October 28, 2024

From Cleerly

Via Business Wire

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

October 28, 2024

From Cleerly

Via Business Wire

Medicare Administrative Contractors Approve Coverage of Cleerly Heart Scans to Medicare Recipients

October 14, 2024

From Cleerly

Via Business Wire

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

March 28, 2024

From Cleerly

Via Business Wire

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

March 05, 2024

From Cleerly

Via Business Wire

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

February 22, 2024

From Cleerly

Via Business Wire

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

February 08, 2024

From Cleerly

Via Business Wire

Cleerly® Launches Cleerly® ISCHEMIA™ Solution for Heart Disease Analysis

January 09, 2024

From Cleerly

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.